"EEG Biomarker Study for Participants in the Neurolief MOOD Trial"

Active, not recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

December 3, 2024

Study Completion Date

November 16, 2025

Conditions
Depression
Interventions
DEVICE

External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation

Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.

Trial Locations (1)

02906

Butler Hospital, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Neurolief Ltd.

INDUSTRY

collaborator

University of North Carolina, Chapel Hill

OTHER

lead

Butler Hospital

OTHER